These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16193577)

  • 1. Aptivus in the hotseat. Excerpts from the FDA hearings.
    Huff B
    GMHC Treat Issues; 2005; 19(5-6):6-8. PubMed ID: 16193577
    [No Abstract]   [Full Text] [Related]  

  • 2. Aptivus capsules granted full FDA approval.
    AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA approves Aptivus (tipranavir).
    Pham PA
    Hopkins HIV Rep; 2005 Jul; 17(4):6-7. PubMed ID: 16419308
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA approves tipranavir.
    IAPAC Mon; 2005 Jul; 11(7):190. PubMed ID: 16676422
    [No Abstract]   [Full Text] [Related]  

  • 5. Tipranavir.
    Gallant J
    Drugs; 2003; 63(15):1619-20. PubMed ID: 12887269
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA approval: tipranavir.
    Sax PE
    AIDS Clin Care; 2005 Aug; 17(8):78. PubMed ID: 16193574
    [No Abstract]   [Full Text] [Related]  

  • 7. New black box warning for ritonavir-boosted tipranavir.
    Ryan CT
    AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669
    [No Abstract]   [Full Text] [Related]  

  • 8. New protease inhibitor offers clinicians hope for better salvage therapy.
    Murphy MJ
    HIV Clin; 2006; 18(1):1-3. PubMed ID: 16838417
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA notifications. Accelerated approval of tipranavir.
    AIDS Alert; 2005 Nov; 20(11):131. PubMed ID: 16363051
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
    TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
    [No Abstract]   [Full Text] [Related]  

  • 11. Tipranavir: new drug. HIV protease inhibitor. A last resort.
    Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipranavir (Aptivus): approval cautiously recommended.
    James JS
    AIDS Treat News; 2005 May; (412):2-3. PubMed ID: 16047408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Desensitization to tipranavir caused by toxicodermia].
    Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
    Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
    [No Abstract]   [Full Text] [Related]  

  • 14. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
    Huff B
    GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA notifications. Tentative approval to Aptivus for combination ART.
    AIDS Alert; 2007 Dec; 22(12):144. PubMed ID: 18411486
    [No Abstract]   [Full Text] [Related]  

  • 16. Boehringer drug for resistant HIV approved.
    AIDS Read; 2005 Aug; 15(8):379, 391. PubMed ID: 16110551
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-HIV agents. Unexpected results from a tipranavir study.
    TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA notifications. Potential serious effect of combination saquinavir-ritonavir.
    AIDS Alert; 2010 Apr; 25(4):45-6. PubMed ID: 20564774
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA notifications. Generic lopinavir/ritonavir approved by FDA.
    AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652
    [No Abstract]   [Full Text] [Related]  

  • 20. Tipranavir (Aptivus) for HIV.
    Med Lett Drugs Ther; 2005 Oct; 47(1219):83-4. PubMed ID: 16247341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.